Large DFS Benefit from Adjuvant Cemiplimab Among Patients at High Risk for Recurrence of Cutaneous Squamous Cell Carcinoma By Ogkologos - June 18, 2025 476 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the C-POST study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Paclitaxel and Carboplatin Not Inferior When Compared with Paclitaxel and Ifosfamide... January 14, 2022 NCI-MATCH Update: More Labs, New Arms, and Initial Findings November 15, 2018 Analysis Shows Women with High Breast Cancer Recurrence Scores Benefit from... October 24, 2019 FDA Approves Durvalumab with Chemotherapy for Mismatch Repair Deficient Primary Advanced... July 19, 2024 Load more HOT NEWS Pharmacokinetic and Pharmacodynamic Interactions Between Anticancer and Antiviral Drugs New Research in Treating Lymphoma and Improving Equity in Cancer Clinical... Why consistent and funded cancer policies are key to improving cancer... FDA Approves Pembrolizumab with Chemotherapy for Primary Advanced or Recurrent Endometrial...
